Beijing Leadman Biochemistry Co Ltd (300289) - Total Assets
Based on the latest financial reports, Beijing Leadman Biochemistry Co Ltd (300289) holds total assets worth CN¥1.76 Billion CNY (≈ $258.19 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300289 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Beijing Leadman Biochemistry Co Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Beijing Leadman Biochemistry Co Ltd's total assets have evolved over time, based on quarterly financial data. See 300289 book value for net asset value and shareholders' equity analysis.
Beijing Leadman Biochemistry Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing Leadman Biochemistry Co Ltd's total assets of CN¥1.76 Billion consist of 62.1% current assets and 38.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 31.9% |
| Accounts Receivable | CN¥85.87 Million | 4.8% |
| Inventory | CN¥88.72 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥20.98 Million | 1.2% |
| Goodwill | CN¥73.53 Million | 4.1% |
Asset Composition Trend (2008–2025)
This chart illustrates how Beijing Leadman Biochemistry Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Leadman Biochemistry Co Ltd (300289) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Leadman Biochemistry Co Ltd's current assets represent 62.1% of total assets in 2025, a decrease from 64.2% in 2008.
- Cash Position: Cash and equivalents constituted 31.9% of total assets in 2025, up from 24.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 5.0% of total assets.
Beijing Leadman Biochemistry Co Ltd Competitors by Total Assets
Key competitors of Beijing Leadman Biochemistry Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
Beijing Leadman Biochemistry Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.99 | 15.64 | 6.32 |
| Quick Ratio | 12.88 | 14.39 | 5.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.03 Billion | CN¥1.04 Billion | CN¥554.43 Million |
Beijing Leadman Biochemistry Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Leadman Biochemistry Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.06 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | CN¥1.78 Billion |
| Market Capitalization | $450.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Leadman Biochemistry Co Ltd's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Beijing Leadman Biochemistry Co Ltd's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Beijing Leadman Biochemistry Co Ltd (2008–2025)
The table below shows the annual total assets of Beijing Leadman Biochemistry Co Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.78 Billion ≈ $259.91 Million |
-2.54% |
| 2024-12-31 | CN¥1.82 Billion ≈ $266.68 Million |
-5.98% |
| 2023-12-31 | CN¥1.94 Billion ≈ $283.65 Million |
-2.94% |
| 2022-12-31 | CN¥2.00 Billion ≈ $292.24 Million |
-14.96% |
| 2021-12-31 | CN¥2.35 Billion ≈ $343.65 Million |
+44.20% |
| 2020-12-31 | CN¥1.63 Billion ≈ $238.32 Million |
-4.99% |
| 2019-12-31 | CN¥1.71 Billion ≈ $250.84 Million |
-0.87% |
| 2018-12-31 | CN¥1.73 Billion ≈ $253.04 Million |
-1.41% |
| 2017-12-31 | CN¥1.75 Billion ≈ $256.65 Million |
+5.48% |
| 2016-12-31 | CN¥1.66 Billion ≈ $243.33 Million |
+0.25% |
| 2015-12-31 | CN¥1.66 Billion ≈ $242.72 Million |
+2.63% |
| 2014-12-31 | CN¥1.62 Billion ≈ $236.50 Million |
+29.92% |
| 2013-12-31 | CN¥1.24 Billion ≈ $182.03 Million |
+10.07% |
| 2012-12-31 | CN¥1.13 Billion ≈ $165.38 Million |
+209.09% |
| 2011-12-31 | CN¥365.66 Million ≈ $53.51 Million |
+41.34% |
| 2010-12-31 | CN¥258.71 Million ≈ $37.86 Million |
+69.09% |
| 2009-12-31 | CN¥153.00 Million ≈ $22.39 Million |
+34.32% |
| 2008-12-31 | CN¥113.91 Million ≈ $16.67 Million |
-- |
About Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnolo… Read more